Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enapotamab Vedotin in Solid Tumors
NCT02988817Phase 2Completed
- Sponsor
- Genmab
- Start
- Nov 2016
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of enapotamab vedotin in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC) and 5 more, sponsored by Genmab. Primary endpoints: Dose-limiting Toxicities, Treatment-emergent Adverse Events and 3 more. Started Nov 2016; status: completed.
02
Drugs
enapotamab vedotin
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)non-small cell lung cancer (NSCLC)thyroid cancer
Beyond the preview
Go deeper on NCT02988817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02988817.